Ticket Price
Free
Licensing Executives Society (LES USA & Canada)
View AgencyWhat is LES International? The Licensing Executives Society International (LESI) has a clear and distinguishable focus on the business aspects of IP from a global perspective with a broad variety of experts from all fronts and sectors dealing with IP transactions, IP valuation and monetization, innovation protection, IP commercialization, IP management, IP licensing and litigation. LESI is an IP thought leader think tank, a non-profit society being strictly non-political and free to grow through the creation of member societies throughout the world irrespective of politics or the state of technology development. LESI offers world leading events (virtual and life), useful resources and publications for deal-making / education / best practices and customized committees based on a network of leaders in their field.
Message OrganiserDoing Life Sciences Deals in 2026 - Licensing, M&A, China and More
Thursday, April 16, 2026
Seminar
Boston
Boston, MA, USA
Event Overview
Join LES USA-Canada's Life Sciences Sector and the Boston Chapter for two informative panels that will discuss structuring life sciences transactions and key issues for biopharma licensing deals.
Panel 1: Structuring Your Life Sciences Transaction in 2026: Licensing vs. M&A vs. Options to Buy vs. Asset Sale
Topics to be covered include:
Key considerations when structuring your life sciences deal
Deal trends – the emergence of options to buy
How to determine when you should do a M&A deal, a license, an option to buy, or an asset sale?
Strategies for doing deals with big pharma
What does big pharma look for in a deal structure?
Is licensing a way to a M&A deal with a big pharma partner?
Panel 2: Navigating Licensing Deals Involving Chinese Life Sciences Assets: Strategies, Challenges, and Opportunities
Topics to be covered include:
Key regulatory and legal frameworks governing deals involving Chinese life sciences assets, and how they differ from Western jurisdictions
How to approach due diligence when evaluating potential Chinese licensees or licensors
Common deal structures for China licensing transactions, including territory splits, milestone payments, and royalty arrangements
Cultural factors and negotiation styles that impact deal-making with Chinese counterparties
IP protection strategies and navigating CFIUS, export controls, and other cross-border regulatory considerations
Emerging trends in deals involving Chinese life sciences assets, including the rise of Chinese biotechs as licensors of innovative therapies
